Pulse Biosciences, Inc. (PLSE) Stock Forecast
PLSE analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 4.83 / 5 from 6 analysts
- Price target
- $62.33 average of analyst targets
- Upside to target
- +40.3% from the latest close
- Next earnings
- November 4, 2026 EPS estimate $-0.35
- 52-week range
- $12.66 – $55.20
PLSE analyst ratings
6 analystsNumber of analysts at each rating.
PLSE price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
PLSE earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.29 | −$0.30 | −$0.28 | — | — | 4 |
| Current fiscal year (2026) | −$1.11 | −$1.13 | −$1.09 | −$0.75 | −46.8% | 4 |
| Next fiscal year (2027) | −$1.17 | −$1.26 | −$1.05 | −$1.11 | −5.6% | 4 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
PLSE revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $521,670 | $400,000 | $600,000 | +506.6% | 6 |
| Current fiscal year (2026) | $2.0M | $1.6M | $2.2M | +480.7% | 6 |
| Next fiscal year (2027) | $5.7M | $1.6M | $8.8M | +178.0% | 6 |
PLSE EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
PLSE revenue: reported and forecast
PLSE EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.28 | −$0.29 | −$0.29 | −$0.29 | −$0.29 | +0.9% | 0 up · 1 down |
| Current fiscal year (2026) | −$1.07 | −$1.10 | −$1.11 | −$1.11 | −$1.11 | +3.5% | 1 up · 0 down |
| Next fiscal year (2027) | −$1.09 | −$1.16 | −$1.15 | −$1.17 | −$1.17 | +7.3% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
PLSE earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; PLSE beat in 7 of 11.
What analysts expect from PLSE
6 analysts cover Pulse Biosciences; their consensus rating is strong buy (4.83 on a 1–5 scale, where 5 is a strong buy). The average price target is $62.33, 40.3% above the latest close of $44.43. Analysts expect earnings of −$1.11 per share for 2026, −46.8% from a year earlier. For 2027 the average estimate is −$1.17 per share on revenue of $5.7 million. Pulse Biosciences beat the EPS estimate in 7 of the last 11 quarters.
Related: PLSE income statement, PLSE key metrics, PLSE chart. See the PLSE stock overview for the latest quote and news.
PLSE forecast FAQ
What is Pulse Biosciences's price target?
The average analyst price target for Pulse Biosciences is $62.33, 40.3% above the latest close of $44.43.
Is Pulse Biosciences a buy, hold or sell?
Of 6 analysts covering Pulse Biosciences, 5 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Pulse Biosciences's EPS forecast?
Analysts forecast −$1.11 per share for 2026 (range −$1.13 to −$1.09); for 2027 the estimate is −$1.17.
What is Pulse Biosciences's revenue forecast?
The average revenue estimate for 2026 is $2.0 million, growth of 480.7%; for 2027 it is $5.7 million.
When does Pulse Biosciences report earnings?
Pulse Biosciences is expected to report results for the quarter ending September 30, 2026 on November 4, 2026; the EPS estimate is $-0.35.
Does Pulse Biosciences usually beat earnings estimates?
Pulse Biosciences reported EPS at or above the analyst estimate in 7 of the last 11 quarters.